

File No: BIO/CT/23/000040
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From:

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated: 18.09.2023

To,

M/s Eli Lilly and Company (India) Pvt. Ltd.,
Plot No. 92, Sector 32, Industrial Area,
Gurugram – 122001, Haryana (India)

Subject: Application for grant of permission to conduct Phase IV clinical trial titled – “A 26-week, multicenter, open-label, single-arm, Phase 4 study to assess the safety of Lyumjev (insulin lispro ultrarapid injection 100 U/mL pen) in adult patients with type 2 diabetes mellitus in India” vide protocol No. I8BMC-ITTA (b) dated 01.05.2023- regarding

Ref.: Your Application No. BIO/CT04/FF/2021/27169 dated 23-Mar-2023

Sir,

With reference to your Application No.: BIO/CT04/FF/2021/27169 dated 23-Mar-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully,

RAJEEV SINGH
RAGHUVANS
HI
(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27
69041015a06564fe67f54b765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=6575E47D94098508F038DC902D
0E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Eli Lilly and Company (India) Pvt. Ltd., Plot No. 92, Sector 32, Industrial Area, Gurugram – 122001, Haryana (India) to conduct clinical trial of the new drug or investigational new drug trial titled as – “A 26-week, multicenter, open-label, single-arm, Phase 4 study to assess the safety of Lyumjev (insulin lispro ultrarapid injection 100 U/mL pen) in adult patients with type 2 diabetes mellitus in India” vide Protocol No.:- I8BMC-ITTA (b) dated 01.05.2023 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date:18-Sep-2023

RAJEEV SINGH
Dr. c/o- CENTRAL DRUGS STANDARD
RAGHVANSI
(Dr. Rajeev Singh Raghavansi)
Digitally signed by RAJEEV SINGH RAGHAVANSI
DN: cn=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHAVANSI,
2.5.4.20-8bdc2f6ad23e4a0bbe239774cde0b3c27
409d1015a0654fe40e7754bb765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=RAGHVANSI, email=rajeevsingh
raghvansi@gmail.com, o=RAJEEV SINGH RAGHAVANSI
Date: 2023.09.19 13:07:35 +05'30"

Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Insulin Lispro Ultrarapid(UR) Injection 100units/ml, solution for Injection		
Therapeutic class:	Antidiabetic		
Dosage form:	Solution for injection in 3 mL cartridge. (Each pack contains 5 pre-filled pens)		
Composition:	Name of Ingredient	Qty/ml	Function
	Insulin Lispro Zinc Crystals USP/Ph.Eur	100 units 3.5mg	Active
	Treprostinil Sodium (IH)	1.06µg	Enabling Excipient
	Sodium citrate Dihydrate (USP-NF/Ph. Eur.)	4.41mg	Buffering agent/Excipient
	Zinc Oxide (USP-NF/Ph. Eur.)	q.s. to provide a Zn ²⁺ content of 39µg	Stabilizer
	Magnesium Chloride, Hexahydrate (USPNF/Ph. Eur.)	1.02mg	Stabilizer
	Metacresol (USP-NF/Ph. Eur)	3.15mg	Preservative/ Stabilizer
	Glycerol (USPNF/Ph. Eur)	12.1mg	Tonicity modifier
	Hydrochloric acid solution(USP-NF/Ph. Eur)	q.s.	pH adjuster
	Sodium hydroxide solution (USP-NF/Ph. Eur)	q.s.	pH adjuster
	Water for Injection (USP/ Ph. Eur./JP)	q.s. to 1 ml	Vehicle
	Indications:	Treatment of diabetes mellitus in adults.	

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	M.V. Hospital for Diabetes Pvt Ltd, #4, West Madha Church Street, Royapuram, Chennai – 600013, Tamilnadu, India	Ethics Committee, Prof. M. Vishwanathan Diabetes Research Centre M. V. Hospital for Diabetes Research Centre, 4, West Madha Church Street, Royapuram, Chennai – 600013, Tamilnadu, India	Dr. Vijay Viswanatha

		EC Reg. No.: ECR/51/Inst/TN/2013/RR-19	
2	Grant Govt. Medical College & Sir J. J. Group of Hospitals OPD 20, Department of Medicine, OPD building, Grant Government Medical College and Sir J J Group of Hospitals, Byculla, Mumbai – 400008, Maharashtra, India	Institutional Ethics Committee, GGMC, Mumbai Grant Government Medical College, J J Road, JJ Hospital Compound Mumbai Central, Mumbai, Mumbai City, – 400008, Maharashtra, India EC Reg. No.: ECR/382/Inst/MH/2013/RR-19	Dr. Hemant Gupta
3	Center for Diabetes and Endocrine Care 410/A, 1st Stage, 3rd Block, HBR Layout, Near BDA Complex, Kalyanagar; Bengaluru, 560043 (India)	Pranav Diabetes Center Ethics Committee. Pranav Diabetes Center Ethics Committee, Unit of Pranav Diabetes Center 57/1, Nanda Complex, Ramamurthy Nagar Main Road, Banaswadi, Bangalore- 560043. EC Reg. No.: ECR/1217/Inst/KA/2019/RR-22	Dr. KM Prasanna Kumar
4	King George Hospital Department of Endocrinology, Super Specialty block 3rd floor, King George Hospital, Andhra Medical College, Maharanipeta, Visakhapatnam – 530002, Andhra Pradesh, India	Institutional Ethics Committee Super Specialty Block 1st floor, King George Hospital, Andhra Medical College, Maharanipeta, Visakhapatnam - 530002, Andhrapradesh EC Reg. No.: ECR/197/Inst/KGH/2013/ RR-20	Dr. Bongi Vivekanand
5	Vijayratna Diabetes Diagnosis and Treatment Center Vijayratna Diabetes Diagnosis & Treatment Centre, Upper Ground Floor, Sumeru Centre, Near Parimal Underbridge and Suvidha Shopping Centre, Paldi, Ahmedabad – 380007, Gujarat, India	Thakershy Charitable Trust Ethics Committee Sushri Jasumatiben Shantilal Surti Charitable General Hospital, (Run by Thakershy Charitable Trust) Opposite Vimanagar, Near Shivranjani Cross Road, Satellite, Ahmedabad-38001 5, Gujarat, India. EC Reg. No.: ECR/696/Inst/GJ/2014/ RR-21	Dr. Sanjeev R Phatak
6	Medical College and Hospital 88, College Street, College Square Kolkata, 700073 (India)	Institutional Ethics Committee For Human Research Medical College Kolkata; 88, College St, Calcutta Medical College, College Square, Kolkata, West Bengal 700073 EC Reg. No.: ECR/287/Inst/WB/2013/RR-19	Dr. Animesh Maiti

7	Rajasthan University of Health Sciences Rajasthan University of Health Sciences Hospital, Sector 11, Kumbha Marg, Pratap Nagar, Jaipur – 302033, Rajasthan, India	RUHS-CMS Institutional Ethics Committee RUHS-CMS, Sector 11, Kumbha Marg, Pratap Nagar, Jaipur – 302033, Rajasthan, India EC Reg. No.: ECR/762/Inst/RJ/2015/RR-22	Dr. Sudhir Bhandari
8	Chellaram Diabetes Institute Chellaram Diabetes Institute, OPD No.55, 1 floor, Lalani Quantum, Bavdhan (Budruk), Pune-Bangalore bypass Highway, NH-4. Pune-411021, Maharashtra, India	Chellaram Diabetes Institute - Institutional Ethics Committee 13th Floor, Lalani Quantum, Pune-Mumbai Highway, Bavdhan Budruk, Pune, 411021, Maharashtra, India EC Reg. No.: ECR/203/Inst/MH/2014/RR-20	Dr. A G Unnikrishnan
9	Osmania General Hospital Room no:306 Department of Endocrinology, 2nd floor, OP Building, Osmania General Hospital, Osmania Medical College, A fzalgunj, Hyderabad, Telangana, India - 500012	Institutional Ethics Committee Osmania Medical College, Koti, Hyderabad - 500095, Telangana, India EC Reg. No.: ECR/300/Inst/AP/2013/RR-19	Dr. Rakesh Sahay
10	Kovai Diabetes Speciality Centre and Hospital Kovai Diabetes Speciality Centre & Hospital, #15, Vivekananda Road, Ram Nagar, Coimbatore-641009, Tamilnadu, India	Institutional Ethics Committee of Kovai Diabetes Speciality Centre & Hospital Kovai Diabetes Speciality Centre & Hospital, #15, Vivekananda Road, Ram Nagar, Coimbatore-641009, Tamilnadu, India EC Reg. No.: ECR/233/Inst/TN/2013/RR-19	Dr. R Balamurugan
11	S. P. Medical College & A G Hospitals Medical OPD, Room No. 16, S. P. Medical College and AG Hospitals, Bikaner – 334003, Rajasthan, India	Ethics Committee S. P. Medical College, Pawan Puri, Bikaner - 334003, Rajasthan, India EC Reg. No.: ECR/27/SP/Inst/RJ/2013/RR-19	Dr. Bal Kishan Gupta
12	Sahyadri Super Speciality Hospital Sahyadri Super Speciality Hospital, 30 C, Erandwane, Karve Road, Pune – 411004, Maharashtra, India	Sahyadri Hospitals Pvt Ltd Ethics Committee Sahyadri Clinical Research and Development Center, 33/34B Makaranda, Bhawe Path, Karve Road, Pune, 411004, Maharashtra, India EC Reg. No.: ECR/493/Inst/MH/2013/RR-19	Dr. Uday Phadke